Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120001 | 0.90 | EPHX2 (0.46) | BRAFEPHX2ROCK2ROCK1PIK3CA | |
| SCHEMBL1366386 | 0.87 | EPHX2 (0.47) | BRAFEPHX2ROCK2ROCK1PIK3CA | |
| SCHEMBL1369010 | 0.87 | EPHX2 (0.47) | BRAFEPHX2ROCK2ROCK1PIK3CA | |
| SCHEMBL1366062 | 0.83 | BRAF (0.62) | BRAFPIK3CAMTORKITPPARG | |
| SCHEMBL1369057 | 0.81 | BRAF (0.62) | BRAFPIK3CAMTORKITKDR | |
| SCHEMBL1368457 | 0.79 | BRAF (0.57) | BRAFPIK3CAMTORKITKDR | |
| SCHEMBL4107604 | 0.78 | BRAF (0.61) | BRAFPIK3CAMTORKITKDR | |
| SCHEMBL1366577 | 0.77 | BRAF (0.60) | BRAFPIK3CAMTORNPC1RAB9A | |
| SCHEMBL4120142 | 0.76 | BRAF (0.53) | BRAFNPC1RAB9AKDR | |
| SCHEMBL1365186 | 0.76 | BRAF (0.59) | BRAFROCK2ROCK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | claimed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K5, MAP3K1, PRKACA | BRAF 35/4885EPHX2 3095/4885ROCK2 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.